Callisto Pharmaceuticals Files IND for SP-304 (Guanilib) in Chronic Constipation and Irritable Bowel Syndrome

NEW YORK--(BUSINESS WIRE)--Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced today that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 (also called Guanilib) for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome.

Back to news